Environmental

VTRS appears broadly in line with diversified pharma peers on emissions and resource intensity, but limited disclosed decarbonization detail reduces relative transparency versus leaders.

The company’s R&D intensity supports lower-carbon, higher-value product development, yet peers with more explicit climate targets and supplier controls remain better positioned.

Manufacturing and packaging footprints are material in pharmaceuticals, and VTRS shows no clear peer-leading evidence of circularity or waste reduction execution in the provided data.

Capital structure metrics do not directly indicate environmental strength, but elevated leverage can constrain peer-relative funding for plant upgrades and emissions-reduction initiatives.

Social

VTRS benefits from a healthcare-sector social license, but peer-relative positioning depends on product quality, access, and supply reliability rather than broad ESG disclosures alone.

R&D spending at roughly 6.9% of revenue supports ongoing product stewardship, yet peers with stronger patient-access and affordability programs may be better positioned socially.

Low stock-based compensation suggests less dilution of employee alignment, but it is only a modest social signal compared with peers’ workforce safety and retention practices.

As a large generic and specialty medicines supplier, VTRS faces recurring quality and shortage expectations, and peers with stronger compliance records typically enjoy better social standing.

Governance

VTRS’s leverage profile is manageable but elevated net debt to EBITDA versus stronger peers can limit governance flexibility and heighten creditor scrutiny.

The company’s stock-based compensation burden is relatively low, which supports shareholder alignment, yet governance quality still depends more on board oversight and disclosure rigor.

Pharmaceutical peers with cleaner capital structures and more consistent capital allocation disclosure generally screen better on governance, especially where restructuring histories remain relevant.

No major governance controversy is provided, but the absence of peer-leading indicators on transparency, risk controls, and capital discipline keeps the score in the moderate range.

Overall Score

VTRS ranks as a moderate ESG performer versus peers, with its strongest relative support coming from healthcare social relevance and its main drag from limited evidence of peer-leading governance and environmental execution.

Score Driver: Elevated Leverage And Limited Peer-Leading ESG Disclosure